Roche YTD September 2017 sales 2b154838-34d9-4f35-9c49-336a96a94c91/...Japan International Europe US Diagnostics ... -250 -150 -50 50 150 250 350 450 ... (adjuvant setting); HR=hormone

Roche

YTD September 2017 sales

Basel, 19 October 2017

3

This presentation contains certain forward-looking statements. These forward-looking

statements may be identified by words such as believes, expects, anticipates, projects,

intends, should, seeks, estimates, future or similar expressions or by discussion of, among

other things, strategy, goals, plans or intentions. Various factors may cause actual results to

differ materially in the future from those reflected in forward-looking statements contained in

this presentation, among others:

1 pricing and product initiatives of competitors;

2 legislative and regulatory developments and economic conditions;

3 delay or inability in obtaining regulatory approvals or bringing products to market;

4 fluctuations in currency exchange rates and general financial market conditions;

5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;

6 increased government pricing pressures;

7 interruptions in production;

8 loss of or inability to obtain adequate protection for intellectual property rights;

9 litigation;

10 loss of key executives or other employees; and

11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to

mean that Roches earnings or earnings per share for this year or any subsequent period will necessarily

match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website

www.roche.com

All mentioned trademarks are legally protected.

4

Group Severin Schwan Chief Executive Officer

YTD Sept 2017 performance

Outlook

5

YTD Sept 2017: Strong sales growth in both

divisions

6 CER=Constant Exchange Rates

2017 2016

CHFbn CHFbn CHF CER

Pharmaceuticals Division 30.6 29.1 5 5

Diagnostics Division 8.8 8.4 5 5

Roche Group 39.4 37.5 5 5

Change in %

YTD Sept 2017: Strong sales growth in US and

International

7

0

2

4

6

8

10

12

14

16

18

Japan International Europe US

Diagnostics

Pharma

CHFbn

+10%

-2% +4%

+2%

+1% +14%

+1%

-1%

+8%

-1%

+2%

+7%

All growth rates at Constant Exchange Rates (CER)

Q3 2017: Sales growth for the sixth consecutive

year

8

2%

6%

4%

6% 6%

4%

8%

7%

5%

4%

5%

6%

5%

7%

6%

4% 4%

6%

3% 3%

4%

6% 6%

0%

2%

4%

6%

8%

10%

Q1

12

Q2

12

Q3

12

Q4

12

Q1

13

Q2

13

Q3

13

Q4

13

Q1

14

Q2

14

Q3

14

Q4

14

Q1

15

Q2

15

Q3

15

Q4

15

Q1

16

Q2

16

Q3

16

Q4

16

Q1

17

Q2

17

Q3

17

All growth rates at Constant Exchange Rates (CER)

YTD Sep 2017: Successful launch activities

Differentiation driving growth

9

EU: Positive CHMP opinion in 1L ALK+ NSCLC

US: 1L under FDA priority review and listing in NCCN

guidelines as category 1 preferred option

EU approval in bladder (1/2L) & lung (2L)

Approved in RMS & PPMS: US, CH, Australia

Positive early feedback from all stakeholders

Additional sales

of recent launches

+900m

Ocrevus

+500m

Alecensa

+122m

Tecentriq

+278m

CHF

PPMS=primary progressive multiple sclerosis; RMS=relapsing forms of multiple sclerosis; NCCN=National Comprehensive Cancer Network;

CHMP=Committee for Medicinal Products for Human Use

Total:

Q3 2017: Sustainable Roche business case

Important milestones achieved

10

HER2 franchise Perjeta in adjuvant BC (APHINITY) US priority review, EU filed

CD20/Hematology

Gazyva in 1L iNHL (GALLIUM)

Venclexta in R/R CLL (MURANO)

Polatuzumab in R/R DLBCL (Ph II)

US priority review, EU approved

Ph 3 met primary endpoint

BTD, EU PRIME designation

Cancer Immunotherapy Tecentriq EU approved in bladder and lung

Lung cancer Alecensa in 1L ALK+ NSCLC US priority review, positive CHMP opinion

Hemophilia A Emicizumab in inhibitors

(HAVEN 1 and 2)

BTD, US priority review, EU accelerated

assessment

Neuroscience Ocrevus Additional approvals in AUS, CAN, CH

Spinal Muscular Atrophy SMN2 splicer (SUNFISH) Ph 1b at WMS* Pivotal Ph III initiated

* WMS=World Muscle Society, October 2017; BTD=breakthrough therapy designation

Roche significantly advancing patient care

Recognition for innovation 2013-present

11

Rank Company #

1 Roche 18

2 Novartis 15

3 BMS 10

4 Merck 9

4 Pfizer 9

18 Breakthrough Therapy Designations

Source: http://www.focr.org/breakthrough-therapies as of October 2017; BR=bendamustin+Rituxan; DLBCL=diffuse large B cell lymphoma; LDAC=low dose cytarabine;

AML=acute myeloid leukemia; ECD=Erdheim-Chester disease; NSCLC=non-small cell lung cancer; PPMS=primary progressive multiple sclerosis; HMA=hypomethylating

agent; CLL=chronic lymphocytic leukemia; IPF=idiopathic pulmonary fibrosis

http://www.focr.org/breakthrough-therapieshttp://www.focr.org/breakthrough-therapieshttp://www.focr.org/breakthrough-therapies

YTD Sept 2017 performance

Outlook

12

Aiming to set new standards of care

Upcoming readouts for CIT & Hematology

13

Readouts:

(Q4 17 to Q2 18)

Most comprehensive lung cancer program

addressing all common backbones Lung

5 trials in non-squamous,

squamous & small cell

lung cancer

Among the leaders in renal cancer GU 1L RCC

First-in-class in colorectal cancer CRC 2/3L CRC

First-in-class in triple negative breast cancer Breast 1L TNBC

First-in-class in non-inhibitor hemophilia A Hemophilia Non-inhibitors and

monthly schedule

Launch of new medicines at a record high

2011 2012 2013 2014 2015 2016 2017

Emicizumab

(filed)

14

2017 outlook raised at HY

15

Group sales growth1 Mid-single digit

Core EPS growth1 Broadly in line with sales growth

Dividend outlook Further increase dividend in Swiss francs

1 At Constant Exchange Rates (CER)

16

Pharmaceuticals Division Daniel ODay CEO Roche Pharmaceuticals

YTD Sept 2017 sales

Innovation

Outlook

17

YTD Sept 2017: Pharma sales

Strong growth in US due to ongoing launches

18 CER=Constant Exchange Rates

2017 2016

CHFm CHFm CHF CER

Pharmaceuticals Division 30,636 29,140 5 5

United States 15,266 13,850 10 10

Europe 6,766 6,916 -2 -2

Japan 2,675 2,690 -1 2

International 5,929 5,684 4 4

Change in %

YTD Sept 2017: Strong sales performance with

increasing contribution from new launches

19 Absolute values and growth rates at Constant Exchange Rates (CER)

-250 -150 -50 50 150 250 350 450 550

Tarceva

Avastin

Tamiflu

Pegasys

Lucentis

Esbriet

Activase/TNKase

Herceptin

Alecensa

MabThera/Rituxan

Actemra/RoActemra

Xolair

Perjeta

Tecentriq

Ocrevus

US

Europe

Japan

International-17%

+357%

+17%

+17%

+13%

+102%

+2%

-2%

-21%

+14%

CHFm

-36%

+11%

+2%

n/a

+4%

0 5 10

Cotellic +

Zelboraf

Alecensa

Tecentriq

Tarceva

CD20

Avastin

HER2

Perjeta

Herceptin

Kadcyla

+6%

-2%

-17%

+357%

+3%

Gazyva/Gazyvaro

Cotellic

MabThera/Rituxan

(Oncology)

-12%

+102%

20

YTD Sept 2017: Oncology with +3% growth

CHFbn

YoY CER growth

YTD Sept 2017 Oncology sales: CHF 19.2bn; All growth rates at Constant Exchange Rates (CER); CIT=cancer immunotherapy;

FL=follicular lymphoma; NCCN=National Comprehensive Cancer Network

Increased competition

Breast cancer reimbursement in France,

CIT competition in US

Perjeta: Strong growth in all regions

Kadcyla: Growth driven by International, US, and EU

US: Cotellic+Zelboraf stable 1/2L market share

EU: Cotellic+Zelboraf increasing; Zelboraf mono declining

US: NCCN category 1 listing in 1L as preferred option

US/EU: 1L filing completed (Positive CHMP opinion)

EU: Approval in lung (2/3L) and bladder (2L and 1L

cisplatin ineligible) achieved

US: Gazyva in 1L FL (GALLIUM) on NCCN guidelines

EU: Approval in 1L FL achieved

HER2 franchise: Growth driven by Perjeta and

Kadcyl